Химия и нефтехимия / Медицинские препараты
Информация о компании
Dennis Jones, Chairman of NASDAQ listed Jones Pharma (JMED) Rings closing bell for the last day of trading for JMED stock completing the firms merger with King Pharmaceuticals (NYSE: KG). JMED shareholders received a valuation of $3.6 billion. Dennis was joined on the platform with Judy Jones, JMED President G Andrew Franz, Michael T Bramblett, and officers of King Pharmaceuticals ...
King Pharmaceuticals, Inc. is a pharmaceutical company that performs basic research and develops, manufactures, markets and sells branded prescription pharmaceutical products and animal health products.